INTRODUCTION: HISTORICAL PERSPECTIVE
established a basis for the hormonal treatment of prostate cancer in a paper describing the beneficial effect of endocrine treatment for locally advanced prostate adenocarcinoma. In 1946 and 1950, Nesbit (4,5) conducted a thorough retrospective analysis of 1818 prostate cancer cases investigating the outcomes of various treatment strategies. He found that a combination of the non-steroidal estrogen, diethylstilbestrol (DES), with bilateral orchiectomy was the best treatment option for the patients with locally advanced disease. The hypothetical mechanism of action of estrogens was speculated to be suppression of testosterone (T) synthesis through negative feedback on the hypothalamo-pituitary axis. Interestingly, the idea of Huggins that there could be a direct estrogenic influence on the prostatic epithelium was ignored. Of possible significance in this context is that the synthetic estrogen Chlorotrianisene, introduced into the clinic in 1951, was shown to be efficient although it did not lower T levels to castrated values (6).
The first evidence of cardiovascular side effects of DES treatment came with the results of Veterans' Administration Cooperative Urological Research Group (VACURG) in 1967 (7). The study was conducted in a randomized fashion, comparing 5 mg DES with placebo, and included more than 2000 cases. One of the major conclusions of the study was that DES at a dose of 5 mg/day caused an extremely high cardiovascular mortality rate. As clinicians became aware of the cardiovascular complications accompanying the use of DES, its use in the treatment of prostate cancer began to decline and two alternatives were introduced to the clinic. Canadian endocrinologist Ferdinand Labrie was, and still is a strong proponent of the use of luteinizing hormonereleasing hormone (LHRH) agonists. He introduced them into clinical treatment of prostate cancer. Then came the first non-steroidal antiandrogen, flutamide, marking the beginning of the era of a combined hormonal treatment (CHT), also known as maximal androgen blockade (MAB). In terms of median survival, the method was superior to LHRH agonist monotherapy (8) and soon got recognition in the urological world. The estrogens were relegated to a small niche in the urological armamentarium.
DISCOVERY OF ESTROGEN RECEPTORS
Whereas pharmaceutical research was more focused on androgens and antiandrogens in the treatment of prostate cancer, basic science was trying to clarify the actions of estrogen in the prostate. In 1962 Elwood Jensen and colleagues (9) identified the first estrogen receptor (ER) in uterine cytosol. Identification was based on the high affinity of ER for 17 -estradiol (E 2 ) and this was only possible when highly radioactive [ 3 H] E 2 was synthesized. More than 20 years after its discovery, ER was cloned with the help of very specific
